| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P |
| Pretreatment |
Trypsin or Pepsin (optional) |
| Positive control |
Melanoma |
| Dilution |
1:50 - 1:200 |
| Isotype |
Rabbit IgG |
| Localization |
Cytoplasm |
S100
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP035-05 |
-
|
| Host |
Rabbit |
| Clone |
ZR115 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon cancer |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Localization |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
1 ml |
Concentrate |
CE/IVD |
Z2419RL |
-
|
| Host |
Rabbit |
| Clone |
ZR115 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon cancer |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Localization |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
7 ml |
Concentrate |
CE/IVD |
Z2419RP |
-
|
| Host |
Rabbit |
| Clone |
ZR115 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon cancer |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Localization |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
0.5 ml |
Concentrate |
CE/IVD |
Z2419RS |
-
|
| Host |
Rabbit |
| Clone |
ZR115 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon cancer |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment corresponding to C-terminal of human S100P protein |
| Localization |
Nucleus, cytoplasm |
S100P
|
Zeta Corporation |
ZR115 |
0.1 ml |
Concentrate |
CE/IVD |
Z2419RT |
-
|
| Host |
Sheep |
| Clone |
Polyclonal |
| Format |
Purified |
| Method |
Double Diffusion, Immunelectrophoresis |
| Isotype |
Mouse IgG1 |
| Immunogen |
Purified human amylase (Type XIII-A) from saliva |
Salivary Amylase
|
Zytomed Systems GmbH |
Polyclonal |
100 µl |
Purified |
RUO |
A12-6124 |
-
|
| Host |
Mouse |
| Clone |
6E3 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Seminoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Immunogen |
SALL4 (partial recombinant protein with GST tag) |
| Localization |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
1 ml |
Concentrate |
CE/IVD |
MOB591 |
-
|
| Host |
Mouse |
| Clone |
6E3 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Seminoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Immunogen |
SALL4 (partial recombinant protein with GST tag) |
| Localization |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB591-01 |
-
|
| Host |
Mouse |
| Clone |
6E3 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Seminoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Mouse IgG1 |
| Immunogen |
SALL4 (partial recombinant protein with GST tag) |
| Localization |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB591-05 |
-
|
| Host |
Mouse |
| Clone |
monoclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Seminoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
Mouse IgG1 kappa |
| Immunogen |
Recombinant protein corresponding to the amino acid residues 954 to 10954 of human SALL4 protein |
| Localization |
Nucleus |
SALL4
|
Zytomed Systems GmbH |
monoclonal |
0.5 ml |
Concentrate |
RUO |
MSK079-05 |
-
|
| Host |
Mouse |
| Clone |
6E3 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Seminoma |
| Dilution |
- |
| Isotype |
Mouse IgG1 |
| Immunogen |
SALL4 (partial recombinant protein with GST tag) |
| Localization |
Nuclear |
SALL4
|
Diagnostic Biosystems |
6E3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM591 |
-
|
| Host |
Rabbit |
| Clone |
SP281 |
| Format |
Concentrate |
| Reactivity |
MS |
| Method |
P, WB |
| Pretreatment |
Citrate |
| Positive control |
Colon, colon adenocarcinoms |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide derived from the C-terminus of human SATB2 protein |
| Localization |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SP281 |
1 ml |
Concentrate |
RUO |
519-5814 |
-
|
| Host |
Mouse |
| Clone |
SATBA4B10 |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Colorectal adenocarcinma |
| Dilution |
- |
| Isotype |
IgG1 |
| Immunogen |
Recombinant protein fragment corresponding to the C-terminus of human SATB2 |
| Localization |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
16 ml |
Ready-to-use |
RUO |
BMS068 |
-
|
| Host |
Mouse |
| Clone |
SATBA4B10 |
| Format |
Ready-to-use |
| Method |
F, P, WB, IP |
| Pretreatment |
EDTA |
| Positive control |
Colon carcinoma |
| Dilution |
- |
| Isotype |
IgG1 |
| Immunogen |
Recombinant fragment of the C-terminal of human SATB2 |
| Localization |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
6 ml |
Ready-to-use |
RUO |
MSG101 |
-
|
| Host |
Mouse |
| Clone |
SATBA4B10 |
| Format |
Concentrate |
| Method |
F, P, WB, IP |
| Pretreatment |
EDTA |
| Positive control |
Colon carcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
IgG1 |
| Immunogen |
Recombinant fragment of the C-terminal of human SATB2 |
| Localization |
Nucleus |
SATB2
|
Zytomed Systems GmbH |
SATBA4B10 |
0.5 ml |
Concentrate |
RUO |
MSK101-05 |
-
|
| Host |
Rabbit |
| Clone |
EP281 |
| Format |
Concentrate |
| Pretreatment |
EDTA pH8 |
| Positive control |
Colon carcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to human SATB2 |
| Localization |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
1 ml |
Concentrate |
CE/IVD |
RMAB112 |
-
|
| Host |
Rabbit |
| Clone |
EP281 |
| Format |
Concentrate |
| Pretreatment |
EDTA pH8 |
| Positive control |
Colon carcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to human SATB2 |
| Localization |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
0.1 ml |
Concentrate |
CE/IVD |
RMAB112-01 |
-
|
| Host |
Rabbit |
| Clone |
EP281 |
| Format |
Concentrate |
| Pretreatment |
EDTA pH8 |
| Positive control |
Colon carcinoma |
| Dilution |
1:50 - 1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to human SATB2 |
| Localization |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
0.5 ml |
Concentrate |
CE/IVD |
RMAB112-05 |
-
|
| Host |
Rabbit |
| Clone |
EP281 |
| Format |
r-t-u |
| Pretreatment |
EDTA pH8 |
| Positive control |
Colon carcinoma |
| Dilution |
gebrauchsfertig |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to human SATB2 |
| Localization |
Nuclear |
SATB2
|
Diagnostic Biosystems |
EP281 |
6 ml |
r-t-u |
CE/IVD |
RMPD112 |
-
|
| Host |
Rabbit |
| Clone |
ZR167 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon, colon carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Localization |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
1 ml |
Concentrate |
CE/IVD |
Z2479RL |
-
|
| Host |
Rabbit |
| Clone |
ZR167 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon, colon carcinoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Localization |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
7 ml |
Ready-to-use |
CE/IVD |
Z2479RP |
-
|
| Host |
Rabbit |
| Clone |
ZR167 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon, colon carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Localization |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
0.5 ml |
Concentrate |
CE/IVD |
Z2479RS |
-
|
| Host |
Rabbit |
| Clone |
ZR167 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Colon, colon carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant fragment (around aa150-350) of human SATB2 protein |
| Localization |
Nucleus |
SATB2
|
Zeta Corporation |
ZR167 |
0.1 ml |
Concentrate |
CE/IVD |
Z2479RT |
-
|
| Host |
Rabbit |
| Clone |
ZR339 |
| Format |
Concentrate |
| Method |
IHC, FFPE |
| Pretreatment |
Citrate o EDTA |
| Positive control |
RCC, paraganglioma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Localization |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
1.0 ml |
Concentrate |
CE/IVD |
Z2645RL |
-
|
| Host |
Rabbit |
| Clone |
ZR339 |
| Format |
ready-to-use |
| Method |
IHC, FFPE |
| Pretreatment |
Citrate o EDTA |
| Positive control |
RCC, Paraganglioma |
| Dilution |
--- |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Localization |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
7 ml |
ready-to-use |
CE/IVD |
Z2645RP |
-
|
| Host |
Rabbit |
| Clone |
ZR339 |
| Format |
Concentrate |
| Method |
IHC, FFPE |
| Pretreatment |
Citrate o EDTA |
| Positive control |
RCC, paraganglioma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Localization |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
0.5 ml |
Concentrate |
CE/IVD |
Z2645RS |
-
|
| Host |
Rabbit |
| Clone |
ZR339 |
| Format |
Concentrate |
| Method |
IHC, FFPE |
| Pretreatment |
Citrate o EDTA |
| Positive control |
RCC, paraganglioma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide corresponding to residues in human SDHB was used as an immunogen |
| Localization |
Cytoplasm, mitochondria |
SDHB
|
Zeta Corporation |
ZR339 |
0.1 ml |
Concentrate |
CE/IVD |
Z2645RT |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
F, P, WB |
| Pretreatment |
Citrate |
| Positive control |
Breast (Carcinoma) |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Immunogen |
Synthetic peptide corresponding to internal region of human smad3. |
| Localization |
Nuclear (mainly) |
SMAD3
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
519-11254 |
-
|
| Host |
Rabbit |
| Clone |
SP306 |
| Format |
Concentrate |
| Method |
P, FL |
| Pretreatment |
Citrate |
| Positive control |
Placenta |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide from the C-terminus of human SMAD4 protein |
| Localization |
Cell membrane, nucleus |
SMAD4
|
Zytomed Systems GmbH |
SP306 |
0.1 ml |
Concentrate |
RUO |
519-6060 |
-
|
| Host |
Rabbit |
| Clone |
SP306 |
| Format |
Concentrate |
| Method |
P, FL |
| Pretreatment |
Citrate |
| Positive control |
Placenta |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide from the C-terminus of human SMAD4 protein |
| Localization |
Cell membrane, nucleus |
SMAD4
|
Zytomed Systems GmbH |
SP306 |
0.5 ml |
Concentrate |
RUO |
519-6062 |
-
|
| Host |
Rabbit |
| Clone |
SP306 |
| Format |
Concentrate |
| Method |
P, FL |
| Pretreatment |
Citrate |
| Positive control |
Placenta |
| Dilution |
1:100 |
| Isotype |
IgG |
| Immunogen |
Synthetic peptide from the C-terminus of human SMAD4 protein |
| Localization |
Cell membrane, nucleus |
SMAD4
|
Zytomed Systems GmbH |
SP306 |
1 ml |
Concentrate |
RUO |
519-6064 |
-
|
| Host |
Rabbit |
| Clone |
EP618Y |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Appendix, Tonsil, Pancreas, Colon adenocarcinoma, Pancreatic Adenocarcinoma |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Nuclear and cytoplasmic |
SMAD4
|
Biocare Medical |
EP618Y |
0.1 ml |
Concentrate |
CE/IVD |
ACI3242A |
-
|
| Host |
Rabbit |
| Clone |
EP618Y |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Appendix, Tonsil, Pancreas, Colon adenocarcinoma, Pancreatic Adenocarcinoma |
| Dilution |
1:100 |
| Isotype |
Rabbit IgG |
| Localization |
Nuclear and cytoplasmic |
SMAD4
|
Biocare Medical |
EP618Y |
0.5 ml |
Concentrate |
CE/IVD |
ACI3242B |
-
|
| Host |
Rabbit |
| Clone |
EP618Y |
| Format |
Ready-to-use |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Appendix, Tonsil, Pancreas, Colon adenocarcinoma, Pancreatic Adenocarcinoma |
| Dilution |
- |
| Isotype |
Rabbit IgG |
| Localization |
Nuclear and cytoplasmic |
SMAD4
|
Biocare Medical |
EP618Y |
6 ml |
Ready-to-use |
CE/IVD |
API3242AA |
-
|
| Host |
Mouse |
| Clone |
1A4 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Smooth muscle or leiomyosarcoma. |
| Dilution |
1:100 |
| Isotype |
IgG2a /κ |
| Immunogen |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
| Localization |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
1.0 ml |
Concentrate |
CE/IVD |
Z2066ML |
-
|
| Host |
Mouse |
| Clone |
1A4 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Smooth muscle or leiomyosarcoma. |
| Dilution |
- |
| Isotype |
IgG2a /κ |
| Immunogen |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
| Localization |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2066MP |
-
|
| Host |
Mouse |
| Clone |
1A4 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Smooth muscle or leiomyosarcoma. |
| Dilution |
1:100 |
| Isotype |
IgG2a /κ |
| Immunogen |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
| Localization |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2066MS |
-
|
| Host |
Mouse |
| Clone |
1A4 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Smooth muscle or leiomyosarcoma. |
| Dilution |
1:100 |
| Isotype |
IgG2a /κ |
| Immunogen |
N-Terminal decapeptide of alpha smooth muscle isoform of actin; acetylated at the N-terminus |
| Localization |
Cytoplasm |
Smooth Muscle Actin (SMA)
|
Zeta Corporation |
1A4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2066MT |
-
|
| Host |
Rabbit |
| Clone |
ZR169 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Leiomyoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Localization |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
1 ml |
Concentrate |
CE/IVD |
Z2465RL |
-
|
| Host |
Rabbit |
| Clone |
ZR169 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Leiomyoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Localization |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
7 ml |
Concentrate |
CE/IVD |
Z2465RP |
-
|
| Host |
Rabbit |
| Clone |
ZR169 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Leiomyoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Localization |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
0.5 ml |
Concentrate |
CE/IVD |
Z2465RS |
-
|
| Host |
Rabbit |
| Clone |
ZR169 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Leiomyoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant human LMO2 protein fragment (around aa 23-140) |
| Localization |
Cytoplasm and Nucleus |
Smoothelin
|
Zeta Corporation |
ZR169 |
0.1 ml |
Concentrate |
CE/IVD |
Z2465RT |
-
|
| Host |
Rat |
| Clone |
YC7 |
| Format |
TCS |
| Method |
F |
| Dilution |
1:20 - 1:200 |
| Isotype |
Rat IgG2b |
| Immunogen |
Synthetic peptide corresponding to part of the native molecule |
Somatostatin
|
Zytomed Systems GmbH |
YC7 |
200 µl |
TCS |
RUO |
619-0155 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit Ig |
| Localization |
Cell Membrane |
Somatostatin Receptor 2A (SSTR2A)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK046-05 |
-
|
| Host |
Rabbit |
| Clone |
polyclonal |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
EDTA |
| Positive control |
Pancreas |
| Dilution |
1:25 - 1:100 |
| Isotype |
Rabbit Ig |
| Localization |
Cell Membrane |
Somatostatin Receptor 5 (SSTR5)
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
RBK051-05 |
-
|
| Host |
Rabbit |
| Clone |
ZR275 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
| Localization |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
1 ml |
Concentrate |
CE/IVD |
Z2591RL |
-
|
| Host |
Rabbit |
| Clone |
ZR275 |
| Format |
Ready-to-use |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma |
| Dilution |
- |
| Isotype |
IgG |
| Immunogen |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
| Localization |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
7 ml |
Ready-to-use |
CE/IVD |
Z2591RP |
-
|
| Host |
Rabbit |
| Clone |
ZR275 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
| Localization |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
0.5 ml |
Concentrate |
CE/IVD |
Z2591RS |
-
|
| Host |
Rabbit |
| Clone |
ZR275 |
| Format |
Concentrate |
| Reactivity |
- |
| Method |
P |
| Positive control |
Melanoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG |
| Immunogen |
Recombinant human SOX-10 protein fragment (around aa 115-269) |
| Localization |
Nucleus |
SOX-10
|
Zeta Corporation |
ZR275 |
0.1 ml |
Concentrate |
CE/IVD |
Z2591RT |
-
|
| Host |
Rabbit |
| Clone |
BC36 |
| Format |
Concentrate |
| Method |
P |
| Pretreatment |
Citrate |
| Positive control |
Lung squamous cell carcinoma |
| Dilution |
1:100 - 1:200 |
| Isotype |
IgG1/Kappa |
| Localization |
Nucleus |
SOX2
|
Biocare Medical |
BC36 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3109A |
-
|